Emblation, a Scottish health tech firm originally based out of Stirlingshire, has launched a $2 million clinical trial in the US in hopes it will transform the progress of its microwave treatments.

Founded by Gary Beale and Eamon McErlean, who met at Edinburgh’s Heriot-Watt University, the company grew from humble beginnings in 2007, gaining startup grants and Scottish Government funding to develop a portable microwave device to treat different skin diseases and disorders.

In 2016, the duo launched their Swift microwave treatment for verrucae and warts which is currently used by over 1,000 clinicians in the US.

However, the device is currently only cleared for general use in dermatology, so cannot be directly marketed as a treatment for warts and verrucae, stymieing its growth.

Emblation’s new trial is set to help their Swift devices achieve a new specific clearance from the US’s Food and Drug Administration, which could extend its reach.

Recommended

• “Bronze Age to Space Age”: Ancient Cremation Site Found at Spaceport
• What are the Benefits of Investing Rural Scots Mobile Connectivity?
• What’s the Current State of 5G, 4G, and 3G in the UK?

For the trail, three dermatologists are set to recruit 110 patients across three US cities, with each patient to receive treatment from one to four months if needed. Experts will review the project’s progress ‘blind’ to mitigate bias.

Going up against existing cryotherapy treatments typically used to treat skin conditions like warts, the study is pivotal for the expansion of Swift’s microwave technology.

“No healthcare system in the world is as commercially important than that in America, which is why it is so heavily regulated,” Dr Matt Kidd, director of research and development at Emblation said.

“This clinical trial is the culmination of years of research and development of our products to target this market. Once the findings are complete, it should transform the way we can market Swift treatments.

“This is a major milestone for us and it has been a long process to get to this stage, ultimately made possible by the fact that Emblation attracted significant investment.

“It is now our very clear hope that the results will allow us to change how our device is labelled, while also demonstrating that Swift® treatments offer clear advantages over cryotherapy.”